ArticleDrugs & aging2007
Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins.
Article in Drugs & aging, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Prevalence of statin-drug interactions in older people: a systematic review.European journal of clinical pharmacology · 2016Pooled it
- Statin Therapy for Primary and Secondary Prevention in Older Adults.Current atherosclerosis reports · 2024Review
- Comparing Important and Well-documented Potential Drug-Drug Interactions between Emergency, Medical, and Surgical ICUs of a Respiratory Referral Center.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022Article
- Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system.Frontiers in pharmacology · 2022Article
- Potential drug-drug interactions in patients with cardiovascular diseases: findings from a prospective observational study.Journal of pharmaceutical policy and practice · 2021Article
- Risk factors for potential drug-drug interactions in patients with chronic obstructive pulmonary disease.Irish journal of medical science · 2020Article
- Assessing Drug-Drug Interaction Potential among Patients Admitted to Surgery Departments in Three Palestinian Hospitals.BioMed research international · 2020Article
- Prevalence and predictors of potential drug-drug interactions in patients of internal medicine wards of a tertiary care hospital in India.European journal of hospital pharmacy : science and practice · 2018Article
- High-Intensity Statin Therapy Is "Too Much," Thus Not Indicated for Very Elderly Patients.Pulse (Basel, Switzerland) · 2018Article
- Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining.European journal of clinical pharmacology · 2018Article
- Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).European journal of drug metabolism and pharmacokinetics · 2017Article
- A Prospective Analysis of Drug Interactions in Patients of Intensive Cardiac Care Unit.Journal of clinical and diagnostic research : JCDR · 2017Article
- Assessment of potential drug-drug interactions and its associated factors in the hospitalized cardiac patients.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2016Article
- Statin drug-drug interactions in a Romanian community pharmacy.Clujul medical (1957) · 2016Article
- Prevalence of Potential and Clinically Relevant Statin-Drug Interactions in Frail and Robust Older Inpatients.Drugs & aging · 2015Article
- Potential drug interactions with statins: Estonian register-based study.Open medicine (Warsaw, Poland) · 2015Article
- Potential statin-drug interactions: prevalence and clinical significance.SpringerPlus · 2014Article
- Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Clinical pharmacokinetics · 2013Review
- Prevention of inappropriate prescribing in hospitalized older patients using a computerized prescription support system (INTERcheck(®)).Drugs & aging · 2013Article
- Agreement among four drug information sources for the occurrence of warfarin drug interactions in Brazilian heart disease patients with a high prevalence of Trypanosoma cruzi infection.European journal of clinical pharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveElderly patients may be at higher risk of drug-drug interactions (DDIs) because of polypharmacy. This study evaluated age-specific differences in the prevalence of clinically relevant potential DDIs (pDDIs) in ambulatory dyslipidaemic patients treated with an HMG-CoA reductase inhibitor (statin). We hypothesised that elderly patients are at higher risk for pDDIs because of the presence of more drugs and drugs with a higher potential for DDIs in this age group.
methodsA total of 2742 dyslipidaemic ambulatory patients treated with a statin were included in this cross-sectional study. Drug treatment was screened for clinically relevant pDDIs using an electronic drug interaction program (DRUG-REAX System).
resultsThe study sample consisted of 483 (17.6%) patients aged < or = 54 years, 732 (26.7%) aged 55-64 years, 924 (33.7%) aged 65-74 years and 603 (22.0%) patients aged > or = 75 years. Patients > or =75 years had significantly more pharmacologically active substances prescribed than patients aged < or =54 years (mean 5.8 vs 3.8, respectively; p < 0.001). Cardiovascular diseases such as coronary heart disease, heart failure or arrhythmias were also significantly more prevalent in patients aged > or = 75 years than in younger patients. The overall prevalence of pDDIs increased significantly from 7.9% in those aged < or = 54 years to 18.4% in patients aged > or = 75 years (p < 0.001). The frequency of both pDDIs associated with statins and non-statin pDDIs increased with age. Risk factors for pDDIs in patients aged > or = 75 years were arrhythmias, heart failure and the number of pharmacologically active substances prescribed. The more frequent prescription of cardiovascular drugs with a high potential for pDDIs (e.g. amiodarone and digoxin) in patients aged > or = 75 years was mainly responsible for the observed increases in statin and non-statin pDDIs in this age group.
conclusionsCompared with younger patients, elderly dyslipidaemic patients are at a higher risk for clinically relevant pDDIs, mainly because of a higher number of drugs prescribed. In addition, patients aged > or = 75 years were prescribed more drugs with a high potential for DDIs, especially drugs used for the treatment of arrhythmias and heart failure. The risk for adverse reactions associated with pDDIs may often be reduced by dose adjustment, close monitoring or selection of an alternative drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.